Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes

2012108 citationsJournal Article

Authors

These studies provide evidence of limited glucose lowering and incretin activity for JNJ-38431055 in subjects with T2DM.

Good health and well-being

Published in: Diabetes Obesity and Metabolism

Volume 14, Issue 8, pp. 709-716

Field-Weighted Citation Impact: 7.83